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If oesophageal carcinoma is detected in the superficial stage, the prognosis is better than for advanced oesophageal carcinoma. But
the factors which predict the prognosis and treatment policy remain unclear. Matrix metalloproteinase-7 (MMP-7) and matrix
metalloproteinase-9 (MMP-9) have been reported to have close associations with tumour invasion and metastasis. In this study, we
retrospectively studied the relations between MMP-7 and MMP-9 expression in immunohistochemistry, clinicopathologic factors, and
prognosis in 55 superficial oesophageal carcinomas. MMP-7 and MMP-9 expression occurred in 23.6% and 47.3% of the patients,
respectively. MMP-7 expression was significantly correlated with the presence of nodal metastasis (P¼0.004). MMP-9 expression
was significantly correlated with the depth of tumour invasion (P¼0.004), lymphatic permeation (P¼0.001), nodal metastasis
(P¼0.049), and pathologic differentiation grade (P¼0.003). By the log-rank test, MMP-7 expression and MMP-9 expression on the
invasive front were related to the prognosis. In multivariate analysis, MMP-9 expression on the invasive front was an independent
prognostic indicator. The combined expression of MMP-7 and MMP-9 may be a good marker for the degree of malignancy of
oesophageal cancer and for the presence of lymphatic metastasis.
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Oesophageal cancer is a disease with a high degree of malignancy,
and its prognosis is worse than that of other gastrointestinal
tumours. The two-year survival rate of patients who receive
surgery for oesophageal cancer is unfavourable, being about 30%
(Krevsky, 1995; Medical Research Council Oesophageal Cancer
Working Party, 2002). For those with risk factors for oesophageal
cancer, which include smoking and drinking, high age (50 to 70
years), and head and neck carcinomas, a common form of
screening is oesophageal endoscopy with iodine solution for
detection of oesophageal carcinoma in the early stage. As a result,
the detected number of superficial oesophageal carcinomas, in
which tumour invasion is limited to the mucosa or submucosa,
with a favourable prognosis has increased (Brodmerkel, 1971;
Endo et al, 1986). With endoscopic ultrasonography (EUS) and
endoscopic mucosal resection (EMR) we positively staged and
treated oesophageal cancer (Yanai et al 1996; Yanai et al, 1997;
Takeo et al, 2001).
Although methods to diagnose superficial oesophageal cancer
have advanced, an important reason for the poor prognosis of
oesophageal cancer is lymph node metastasis, even in superficial
carcinoma. Thus, the existence of lymph node metastasis
determines the strategy for treatment and the estimated prognosis
of oesophageal cancer. Oesophageal cancer limited to the
epithelium (EP) and lamina propria mucosae (LPM) has little
lymph node metastasis. But the likelihood of lymph node
metastasis for cancer with muscularis mucosae (MM) invasion is
almost 10%. The possibility of lymph node metastasis with
invasion of the submucosa (SM) increases to as much as 30% to
50% (Bogomoletz et al, 1989; Kodama et al, 1998). Thus, for
tumours with MM and SM invasion, operation is considered
necessary even in the case of superficial oesophageal tumours.
Thus, new parameters for lymph node metastasis and prognosis
are needed for tumours with MM and SM invasion.
Recently, the matrix metalloproteinase (MMP) family has been
reported to play important roles in the invasion and metastasis of
colon cancer and gastric carcinoma (Mc Donnell et al, 1991;
Wilson et al, 1997; Adachi et al, 1998; Yamashita et al, 1998). In
particular, MMP-7 is characterized by (1) broad and strong
proteolytic activity against a variety of extracellular matrix
substrates such as collagens, proteoglycans, laminin, fibronectin,
and casein, (2) lack of a c-terminal domain, so it is not regulated
easily by tissue inhibitor of metalloproteinases (TIMP), and (3)
production by tumour cells themselves (Miyazaki et al, 1990;
Matrisian, 1992; Baragi et al, 1994; Adachi et al, 1998). It has been
reported that MMP-7 is present in gastric, colorectal, head and
neck, and hepatocellular cancers (Yoshumoto et al, 1993;
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has attracted much attention because it is reported to be present in
the tumour invasive front (Adachi et al, 1998; Adachi et al, 2001;
Lin et al, 2002). It has also been reported to have a correlation with
invasion and metastasis in oesophageal cancer (Adachi et al, 1998;
Yamamoto, 1999; Ohashi, 2000; Yamashita, 2000).
On the other hand, the members of the MMP family form a
cascade and activate each other. MMP-9, which works directly to
degrade the extracellular matrix (Parsons et al, 1997), is the last
stage in the cascade. It decomposes type IV collagen, which is the
chief component of basement membrane, and also promotes
tumour invasion and metastasis. MMP-9 expression in tumours
was reported in gastric, colon, pancreatic, and cervical cancers
(Torii et al, 1998; Baker et al, 2002; Kato et al, 2002; Nagakawa
et al, 2002).
To determine the appropriate treatment for superficial oeso-
phageal carcinoma, we retrospectively studied expression of MMP-
7 and MMP-9 and investigated clinical pathological factors and
outcomes in superficial oesophageal cancer treated by endoscopic
and surgical resection.
MATERIALS AND METHODS
Patients and tissue samples
Fifty-five patients (average age 65. 2 years old, male/female ratio
41/14), consisting of 34 with surgical resection for superficial
oesophageal cancers between 1995 and 1999, and 21 with EMR
between 1995 and 2001 at Yamaguchi University Hospital were
studied. No patient had received irradiation treatment or
chemotherapy before the resection. Forty-four oesophageal
squamous cell carcinomas (SCC) and 1 adenocarcinoma were
included. The age range for the 55 patients was 44–85 years (mean,
65.2 years). Lymph node metastases were detected in twelve
patients but none of the patients had distant metastasis. The depth
of superficial oesophageal tumour invasion was EP in 9 cases, LPM
in 6 cases, MM in 16 cases and SM in 24 cases. All 55 patients were
followed up. The median follow-up period after the first treatment
was 34.2 months (1–81 months), at which time 15 patients had
already died. The reasons for death were as follows: oesophageal
carcinoma for 5, (survival time 9–47 months, average 22.8
months), other carcinomas for 3, and cerebral infarction for 3.
One of the deepest sections from each tumour was selected for
evaluation. It was pathologically classified by standard methods
using hematoxylin and eosin (HE) staining as follows (Japanese
Society for Esophageal Disease, 2001). According to the depth of
invasion, we classified the tumours into 4 groups: EP, LPM, MM,
and SM. The tumours were classified as well differentiated SCC,
moderately differentiated SCC, poorly differentiated SCC, and
others. We also examined whether lymphatic permeation, venous
invasion, and nodal metastasis were present. Gross features of the
superficial oesophageal cancer were classified as elevated, flat and
depressed. Infiltrative growth patterns (inf) were classified into
three types: a (expansile type: expansile growth of tumour nests
forming a distinct border with surrounding tissue), b (inter-
mediate type: intermediate pattern, between inf-a and inf-g) and g
(infiltrative type: infiltrative growth of tumour nests forming an
indistinct border with surrounding tissue).
Immunohistochemistry for MMP-7 and MMP-9 was performed
for each case. The patient’s prognosis after treatment was
investigated by examining the medical record. Written informed
consent was obtained from all the patients or their relatives.
Immunohistochemistry
Four-micrometer sections of paraffin-embedded specimens from
the deepest parts of the tumours were dewaxed in xylene, and
rehydrated through a series of graded ethanol. After heating in a
microwave oven (500watts) for 6min, the sections were allowed to
cool to room temperature in cold water. Endogenous peroxidase
was blocked with 3% hydrogen peroxide in methanol for 30min.
Sections were washed twice for 3min in phosphate–buffered saline
(PBS). Primary mouse monoclonal anti-human MMP-7, purified
IgG (141-7B2; Fuji Chemical, Toyama, Japan, diluted 1:100) and
anti-human MMP-9, and purified IgG (56-2A4; First Fine
Chemical, Toyama, Japan, diluted 1:100) were added and
incubated in a moist chamber overnight at 41C. After three washes
in PBS for 5min each time, samples were incubated with Histofine
simple stain MAX-PO (M)(Nichirei, Tokyo) for 30min at room
temperature, according to the manufacturer’s instructions. The
reactions were stopped by washing the sections three times for
5min in PBS. Positive reactions were visualized with hydrogen
peroxide containing 0.05% 3,30-diaminobenzine (DAB) in PBS. The
slides were counterstained with Mayer’s hematoxylin solution for
nuclei. Negative control sections were made by omitting the
primary antibody.
The score was calculated as the percentage of cells stained
positively among tumour cells counted. Four high-power fields
( 400) were selected. Cases were considered positive when over
10% of carcinoma cells were stained. Immunostaining signals at
the invasive front were also calculated and the cases were
considered positive when not less than 10% of cells at the invasive
front were stained (Kawano et al, 1997; Yamamoto et al, 1999). All
specimens were evaluated by two investigators (Y.T., T.Y.) who
were blinded to the patients’ clinical information. Disagreements
were reviewed and a conclusive judgment was made.
Statistical analysis
Statistically significant differences were determined by
Fisher’s exact probability test for gender, lymphatic permeation,
venous invasion, and nodal metastasis. Pearson’s chi-squared test
was performed for gross feature classification, histological
differentiation grade, and infiltrative growth pattern. Other factors
such as age and depth of invasion were subjected to the Cochran-
Armitage trend test. The P-value was calculated using exact
methods.
Probability distributions of overall survival were calculated
using the Kaplan-Meier method and compared by the log-rank
test. To determine independent factors that were significantly
related to the prognosis for patients with oesophageal cancer,
multivariate analysis was performed using Cox’s proportional
hazards model with a stepwise procedure. The variables included
in the multivariate analysis were the following categories: gender,
age (under 59, 60–64, 65–69, and over 70), gross features
(elevated, flat, depression), depth of invasion (EP, LPM, MM,
SM), histological differentiation grade (well differentiated SCC,
moderately differentiated SCC, poorly differentiated SCC, and
others), lymphatic permeation (positive, negative), venous inva-
sion (positive, negative), infiltrative growth patterns (a,b,g), nodal
metastasis (positive, negative), MMP-7 (positive, negative), MMP-7
on the invasive front (positive, negative), MMP-9 (positive,
negative), and MMP-9 on the invasive front (positive, negative).
For all statistical tests, a P value of less than 0.05 was defined as
statistically significant. All analyses were performed using SAS
version 6.11 (SAS Institute Inc., Cray, NC, USA).
RESULTS
Expression of MMP-7
The cytoplasms and cell membranes of carcinoma cells were
stained brown for MMP-7, but stromal cells, except for some
monocytes, were not stained (Figure 1A, B). Expression of MMP-7
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was immunostained at the invasive front in 7 cases (12.7%). MMP-
7 expression was significantly correlated with positive nodal
metastasis (P¼0.004) only. In the invasive front, MMP-7
expression was significantly correlated with deep tumour invasion
(P¼0.013), positive lymphatic permeation (P¼0.010), positive
nodal metastasis (P¼0.004) and unclear infiltrative growth pattern
(P¼0.043).
Expression of MMP-9
Expression of MMP-9 was observed in the cytoplasm of carcinoma
cells, stromal fibroblasts and vascular endothelial cells (Figure 1C,
D). It was detected in 26 cases (47.3%) (Table 2). At the invasive
front MMP-9 was observed in 22 cases (40%). Tumours with MM
and SM invasion had significantly more MMP-9 expression
(P¼0.004). Poorly differentiated SCC had more MMP-9 expres-
sion than moderately and well differentiated carcinomas
(P¼0.003). MMP-9 expression was significantly correlated with
positive lymphatic permeation (P¼0.001), and positive nodal
metastasis (P¼0.049). On the other hand, expression of MMP-9 at
the invasive front was significantly correlated with deep tumour
invasion (P¼0.001), positive lymphatic permeation (P¼0.012),
and positive nodal metastasis (P¼0.047).
Coexpression of MMP-7 and MMP-9
We divided subjects into two groups with coexpression of MMP-7
and MMP-9, and the others. Coexpression was detected in 11 cases
(20%) (Table 3). MMP-7 expression alone was found in 2 cases
(4%), and MMP-9 expression alone in 15 cases (27%). Twenty-
seven cases (49%) were negative for both MMP-7 and MMP-9. At
the invasive front, the numbers of cases with coexpression, only
MMP-7, only MMP-9 and negative expression of MMP-7 and
MMP–9 were 6 (11%), 1 (2%), 16 (29%), and 32 (58%),
respectively. Coexpression of MMP-7 and MMP-9 was significantly
correlated with deep tumour invasion in MM and SM (P¼0.008),
and positive nodal metastasis (P¼0.008). Moreover, expression at
the invasive front was significantly correlated with deep tumour
invasion (P¼0.025), positive lymphatic permeation (P¼0.026)
and positive nodal metastasis (P¼0.017).
Survival analysis
Patients with MMP-7 expression-positive cancer and MMP-9
invasive front-positive cancer had significantly shorter overall
survival times than those with negative expression (P¼0.025,
P¼0.026, respectively) (Figures 2, 3). In the multivariate analysis,
only expression of MMP-9 at the invasive front had prognostic
significance for overall survival (P¼0.004, risk ratio 5.68). The
other factors were not statistically significant (Table 4). However,
older patients tended to have poorer prognoses at the ages of 60–
64 (P¼0.787), 65–69 (P¼0.138), and over 70 (P¼0.063).
DISCUSSION
MMP-7 plays important roles in tumour invasion and metastasis.
There have been some reports on MMP-7 in oesophageal cancer.
Figure 1 Immunohistochemical staining of oesophageal cancer for MMP-7 and MMP-9. (A) MMP-7-positive SCC; MMP-7 was stained in cancer cell
cytoplasm, (B) MMP-7-negative SCC, (C) MMP-9-positive SCC; MMP-9 was stained in tumour cytoplasm, (D) MMP-9-negative SCC ( 400).
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immunohistochemically, and showed that cancers with SM
invasion had significantly more MMP-7 expression (44%) than
those with MM invasion. They also reported that 61.9% of positive
venous invasion cases had expression of MMP-7, which was
significantly more than in negative cases. Yamamoto et al. (1999)
used immunohistochemistry to study 100 oesophageal cancers at
the invasive front. They reported that the MMP-7 expression rate
was 49% and that the expression was related to the depth of
invasion (Po0.0001), advanced tumour stage (P¼0.0159), recur-
rence (P¼0.0002), recurrence within the first operative year
(P¼0.002), disease-free time (P¼0.0007) and overall survival
(P¼0.0004). Yamashita et al. (2000) reported that the MMP-7 m-
RNA expression rate detected by northern blot analysis was 65% in
48 cases, and that expression was related to nodal metastasis
(Po0.05) and prognosis (Po0.01). It was also determined to be of
prognostic significance for predicting overall survival (P¼0.0005)
in multivariate analysis.
In our study, MMP-7 expression was significantly related to
nodal metastasis (P¼0.004) and a less favourable prognosis
(P¼0.025). Thus, examination for the presence of MMP-7 in
tumour biopsy specimens before treatment is expected to be useful
for decision making about the treatment course and to predict
prognosis. There was no correlation with age, gender, gross
features, deep growth invasion, differentiation grade, lymphatic
permeation, venous invasion, or infiltrative growth pattern. The
rate of MMP-7 expression was a little low, 23.6% of 55 patients,
because we examined only superficial oesophageal cancer.
On the other hand MMP-7 expression at the invasive front was
also correlated with positive nodal metastasis. Cases with tumour
invasion of the SM had significantly more MMP-7 expression at
the invasive front. Moreover, we newly showed that MMP-7
expression at the invasive front was significantly correlated with
positive lymphatic permeation and unclear infiltrative growth
pattern. These results supported the possibility of an effect of
MMP-7 on the tumour invasive front. At the invasive front of
oesophageal cancer, MMP-7 may have an important role in
invasion and metastasis.
There have been reports about the roles of MMP-9 expression in
tumour invasion and metastasis, but this is controversial in
oesophageal cancer. Ohashi et al. (2000) immunohistochemically
studied 148 oesophageal cancers, and found that tumours with SM
invasion had higher MMP-9 expression (51.9%) than those with
MM invasion. They showed that the presence of venous invasion
was related to MMP-9 expression, as it occurred in 65.1% of cases.
But Koyama et al. (2000) found 60% expression in immunohis-
tochemistry for 39 oesophageal tumours, and reported that there
was no relation of MMP-9 expression to any clinicopathologic
factor. They found a relation of MMP-9 expression to venous
invasion (P¼0.0022) by zymography, so active MMP-9 protein
might lead to tumour invasion. Sato et al. (1999) found no relation
Table 2 Association of MMP-9 expression and clinicopathologic findings
MMP-9
MMP-9 at
invasive front
Positive Negative P Positive Negative P
Variables (n¼26) (n¼29) value (n¼22) (n¼33) value
Gender
Male 22 19 0.13 18 23 0.361
Female 4 10 4 10
Age
%59 7 9 0.562 5 11 0.95
60–64 8 1 7 2
65–69 5 5 4 6
70% 61 4 61 4
Gross features
Elevated 6 5 0.867 5 6 0.871
Flat 1 1 1 1
Depressed 19 23 16 26
Depth of invasion
EP 1 8 0.004* 0 9 0.001*
L P M 24 24
MM 7 9 5 11
SM 16 8 15 9
Differentiation grade
SCC (well) 2 8 0.003* 2 8 0.32
SCC (moderately) 12 19 12 19
SCC (poorly) 10 1 6 5
Others 2 1 2 1
Lymphatic permeation
Positive 16 5 0.001* 13 8 0.012*
Negative 10 24 9 25
Venous invasion
Positive 5 3 0.455 5 3 0.244
Negative 21 26 17 30
Infiltrative growth pattern
a 11 17 0.633 8 20 0.298
b 14 11 13 12
g 11 11
Nodal metastasis
Positive 9 3 0.049* 8 4 0.047*
Negative 17 26 14 29
*Significant.
Table 1 Association of MMP-7 expression and clinicopathologic findings
MMP-7
MMP-7 at
invasive front
Positive Negative P Positive Negative P
Variables (n¼13) (n¼42) value (n¼7) (n¼48) value
Gender
Male 11 30 0.447 6 35 0.664
Female 2 12 1 13
Age
%59 2 14 0.461 1 15 0.851
60–64 4 5 3 6
65–69 3 7 2 8
70% 41 6 1 1 9
Gross features
Elevated 4 7 0.291 3 8 0.057
Flat 1 1 1 1
Depressed 8 34 3 39
Depth of invasion
EP 0 9 0.06 0 9 0.013*
LPM 2 4 0 6
MM 2 14 0 16
SM 9 15 7 17
Differentiation grade
SCC (well) 2 8 0.569 0 10 0.334
SCC (moderately) 9 22 6 25
SCC (poorly) 1 10 1 10
Others 1 2 0 3
Lymphatic permeation
Positive 8 13 0.059 6 15 0.01*
Negative 5 29 1 33
Venous invasion
Positive 1 7 0.664 1 7 1
Negative 12 35 6 41
Infiltrative growth pattern
a 4 24 0.186 1 27 0.043*
b 81 7 5 2 0
g 11 1 1
Nodal metastasis
Positive 7 5 0.004* 5 7 0.004*
Negative 6 37 2 41
*Significant.
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sex, age or differentiation grade. Murray et al. (1998)also reported
that MMP-9 expression had no relation to staging.
In our study, MMP-9 expression at the invasive front was
significantly related to deep invasion, positive lymphatic permea-
tion, and positive nodal metastasis, like MMP-7 expression at the
invasive front. In the MMP family activation cascade, MMP-9 is
downstream of MMP-7 and destroys the extracellular matrix
directly (Parsons et al, 1997). Judging from the above, it is
reasonable to consider that MMP-9 expression behaves similarly to
MMP-7 expression. Moreover, in both univariate and multivariate
analyses, MMP-9 expression at the invasive front was an
independent prognostic factor. Thus MMP-9 expression at the
invasive front in the resected tumour may indicate the necessity
for additional treatment after operation.
MMP-9 expression for the whole tumour was also related to the
oesophageal tumour differentiation grade, along with depth of
invasion, lymphatic permeation and nodal metastasis. MMP-9 may
have a role in the destruction of the extracellular matrix of the
tumour overall, not only at the invasive front. Thus, MMP-9
expression examined by a pre-treatment biopsy of the tumour
surface may be a good marker for lymphatic permeation, nodal
metastasis and depth of invasion. The presence of MMP-9
expression may be important to determine the strategy for
treatment.
We examined the significance of MMP-7 and MMP-9 coexpres-
sion and classified patients into two groups, those with both MMP-
7-positive and MMP-9-positive expression and the others. Coex-
pression was significantly correlated with deep invasion into the
MM and SM, and nodal metastasis. Although it had no relation
with minute changes like lymphatic permeation, coexpression of
MMP-7 and MMP-9 may suggest nodal metastasis in oesophageal
cancer.
Table 3 Association of MMP-7+MMP-9 coexpression and clinicopatho-
logic findings
MMP-7+MMP-9
Invasive front
MMP-7+MMP-9
Positive Others P Positive Others P
Variables (n¼11) (n¼44) value (n¼6) (n¼49) value
Gender
Male 10 31 0.255 5 36 1
Female 1 13 1 13
Age
%59 1 15 0.341 1 15 0.863
60–64 4 5 2 7
65–69 3 7 2 8
70% 31 7 1 1 9
Gross features
Elevated 4 7 0.158 2 9 0.134
Flat 1 1 1 1
Depressed 6 36 3 39
Depth of invasion
EP 0 9 0.008* 0 9 0.025*
LPM 0 6 0 6
MM 2 14 0 16
SM 9 15 6 18
Differentiation grade
SCC (well) 1 9 0.452 0 10 0.132
SCC (moderately) 8 23 6 25
SCC (poorly) 1 10 0 11
Others 1 2 0 3
Lymphatic permeation
Positive 7 14 0.082 5 16 0.026*
Negative 4 30 1 33
Venous invasion
Positive 1 7 1 1 7 1
Negative 10 37 5 42
Infiltrative growth pattern
a 2 26 0.058 1 27 0.064
b 81 7 4 2 1
g 11 1 1
Nodal metastasis
Positive 6 6 0.008* 4 8 0.017*
Negative 5 38 2 41
*significant.
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Figure 2 Comparison of overall survival curves for patients with MMP-7-
positive and MMP-7-negative superficial oesophageal cancer. MMP-7-
positive patients have a less favourable prognosis than those who are MMP-
7-negative.
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Figure 3 Comparison of overall survival curves for patients with MMP-9-
positive and MMP-9-negative superficial oesophageal cancer. Patients who
were MMP-9-positive at the invasive front had a less favourable prognosis
than those who were MMP-9-negative at the invasive front.
Table 4 Multivariate analysis of MMP-7, MMP-9 and pathologic
parameters
Risk ratio 95% CI P value
MMP-9 invasive front
Negative 1
Positive 5.68 (1.75B18.444) 0.004*
Age (years)
%59 1
60–64 0.758 (0.102B5.62) 0.787
65–69 3.652 (0.659B20.222) 0.138
70% 4.645 (0.918B23.491) 0.063
CI¼Confidence Interval *Significant.
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MM and SM have about 10–50% lymph node metastasis, so it is
often difficult to choose between EMR and surgical resection.
Immunohistochemistry for MMP-7 and MMP-9 before treatment
in these cases will provide important information for treatment
policy. MMP-7-negative and MMP-9-negative biopsy findings
might be useful as an indication for EMR without operation
because they could predict shallow depth of invasion and little
lymphatic metastasis.
In conclusion, combined MMP-7 and MMP-9 expression
may be a good marker for the malignancy level of oesophageal
cancer and for the presence of lymphatic metastasis, not
venous invasion. MMP-9 expression at the invasive front
can be a significant prognostic variable for predicting overall
survival.
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